PepGen(US:PEPG) Prnewswireยท2025-02-04 21:30Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving PepGen Inc. and its officers or directors [1] Group 1: Company Overview - PepGen Inc. is a company listed on NASDAQ under the ticker PEPG [1] - The company is currently facing scrutiny due to a clinical hold notice received from the FDA regarding its IND application for a clinical trial related to Duchenne muscular dystrophy [2] Group 2: Recent Developments - On December 16, 2024, PepGen announced it received a clinical hold notice from the FDA, which will provide an official letter within 30 days [2] - Following this announcement, PepGen's stock price decreased by $0.17, or 3.63%, closing at $4.51 per share on the same day [2] Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]